914P - Comorbidities and adverse events in advanced and recurrent ovarian cancer patients in France

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Ovarian Cancer
Complications/Toxicities of Treatment
Cancer in Special Situations
Presenter Olivia Le Saux
Citation Annals of Oncology (2014) 25 (suppl_4): iv305-iv326. 10.1093/annonc/mdu338
Authors O. Le Saux1, A. Taylor2, V. Chia3, D. Pillas2, G. Kafatos2, G. Freyer4
  • 1Department Of Medical Oncology, Centre Hospitalier Lyon-Sud, 69495 - Lyon/FR
  • 2Centre For Observational Research, Amgen Ltd, Uxbridge/GB
  • 3Center For Observational Research, Amgen Inc, Thousand Oaks/US
  • 4Department Of Medical Oncology, Centre Hospitalier Lyon-Sud, Lyon/FR



Few observational studies have reported adverse events and comorbidities in European ovarian cancer patients. We conducted a retrospective study to address these areas.


A retrospective cohort study of advanced (stage IIIB-IV) or recurrent ovarian cancer (OC) patients treated by hospital or cancer centre-based physicians (n = 23) was conducted in France. 127 patients diagnosed with OC between 2009 and 2012 and with a minimum follow-up of 6 months were included. Retrospective information on comorbidities, treatment-related adverse events (AEs) (captured over a maximum 1 year period), and deaths was abstracted into case report forms.


Of the 127 patients, 92 (72.4%) had advanced OC and 35 (27.6%) had recurrent OC; the median age was 62 years. 86.6% of patients had surgery performed during the most recent admission. 35 (27.6%) patients recurred after initial presentation, of which 16 were highly platinum sensitive (recurrence more than 12 months after stopping platinum based therapy), 11 were platinum partially-sensitive (recurrence 6-12 months of stopping platinum based therapy), 7 were platinum resistant (recurrence within 6 months of stopping platinum-based therapy or progression while receiving 2nd or later line platinum based therapy), and 1 was platinum refractory (recurrence within 6 months of the start date of 1st-line platinum-based therapy). A total of 73 comorbidities were reported in 44 patients (34.6% of patients). Vascular (10.2%), metabolism (7.1%), respiratory (5.5%), and psychiatric disorders (5.5%) were the most common. Incidence of AEs was 77.2%, of which 12.6% were classified as serious. The most common AEs were anaemia (16.5%), hematologic events (12.6%), taste change (11.8%), and headache (7.1%). Throughout the follow-up period, 12 patient deaths were reported (6 due to disease progression).


In a European hospital-based study of advanced or recurrent ovarian cancer patients, one in three patients were reported to have a comorbidity, and four in five reported a mild adverse event. The incidence rates reported in this study are comparable to those reported in previous European-based studies.


A. Taylor, V. Chia and G. Kafatos: is employed by Amgen Ltd and owns Amgen stock;

D. Pillas: is employed by Amgen Ltd; G. Freyer: is a consultant for Amgen France. All other authors have declared no conflicts of interest.